CS0159 and Semaglutide Combination Therapy Under Evaluation for MASH in Obese T2DM Patients

MASH (Metabolic dysfunction-associated steatohepatitis) is a severe form of NAFLD (Non-alcoholic fatty liver disease) characterized by hepatic inflammation, fibrosis, and steatosis, often progressing to cirrhosis and hepatocellular carcinoma. Current treatments are limited, with lifestyle modifications being primary. Semaglutide, a GLP-1 receptor agonist, has shown promise in weight loss and improving glycemic control in type 2 diabetes and obesity, but its direct efficacy in resolving MASH and fibrosis, especially at lower doses (e.g., 1 mg weekly), can be suboptimal. The need for more effective therapies, potentially through combination approaches targeting multiple pathways, remains high for this complex metabolic disease.

This is an exploratory study evaluating the combination of CS0159 and Semaglutide in patients diagnosed with MASH, obesity, and type 2 diabetes. Specific details regarding the study design, such as patient n, exact dosing regimens, route of administration, frequency, duration, primary endpoints, or control arm, are not provided in the abstract. The study aims to assess the efficacy and safety of this novel combination therapy in the specified patient population.